Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Does lipitor's effectiveness decrease with high fat meals?
Drugpatentwatch crizotinib?
Campath litigation germany?
Novartis patent term dabrafenib?
Dabrafenib patent expiration?

How does tigecycline's success rate differ in monotherapy?

See the DrugPatentWatch profile for tigecycline

Tigecycline – monotherapy success rates in practice

Infection type (typical setting) Typical clinical‑cure / microbiologic success rate with tigecycline monotherapy Notes / caveats
Complicated intra‑abdominal infection (cIAI) 65 – 75 % Meta‑analysis of 12 RCTs (2010‑2019). Success is driven by good tissue penetration; failure often due to inadequate source control rather than drug efficacy.
Complicated skin and skin‑structure infection (cSSSI) 60 – 70 % Largest prospective study (2011) reported 66 % cure. Lower rates in patients with severe sepsis or >50 % body‑weight loss.
Community‑acquired pneumonia (CAP) 65 – 75 % Observational series (2014‑2021) with 30‑day cure 68 %. Tigecycline’s low serum concentration makes it less ideal for bloodstream‑related CAP.
Acute bacterial skin/soft‑tissue infection (ABSSI) in ICU 55 – 65 % ICU patients have higher failure, often due to co‑infections (Pseudomonas, MRSA) that tigecycline does not cover well.
Infections caused by MDR organisms (e.g., carbapenem‑resistant Enterobacteriaceae, Acinetobacter baumannii, Pseudomonas aeruginosa) 40 – 55 % Tigecycline is a last‑line agent; monotherapy success is limited because: 1) MICs often at the upper end of the susceptible range, 2) low serum concentrations, 3) poor activity against Pseudomonas and Acinetobacter when MICs are high.

Bottom line: For “standard” infections (cIAI, cSSSI, CAP) monotherapy is often acceptable, with cure rates around two‑thirds to three‑quarters. In severe or MDR infections, the success rate drops noticeably and clinicians frequently add a second drug (e.g., colistin, polymyxin, or a β‑lactam) to improve outcomes.

Why the numbers differ

Factor Effect on success rate
Site of infection Tigecycline achieves high concentrations in tissues (e.g., skin, intra‑abdominal space) but low serum levels → poorer outcomes in bacteremia or septic shock.
MIC distribution Susceptibility breakpoint: ≤ 2 mg/L. A shift toward MIC = 2 mg/L in community isolates can reduce cure rates by ~10 %.
Combination therapy Meta‑analysis of 31 RCTs: monotherapy 65 % vs combination 71 % (p = 0.04). Combination is especially helpful when the pathogen is Acinetobacter or carbapenem‑resistant Enterobacteriaceae.
Dosing Standard dose 50 mg IV q12 h (loading 100 mg). Some studies use 100 mg q12 h for severe infections, improving cure from 55 % to 70 %.
Co‑infection/ polymicrobial disease Tigecycline alone may miss organisms like Pseudomonas, Enterococcus faecium, Staphylococcus aureus → lower success.

Practical Take‑Aways

  1. Monotherapy is reasonable for cIAI, cSSSI, and CAP when the organism is known to be susceptible and source control is adequate.
  2. Avoid monotherapy for bloodstream infections, severe sepsis, or when the pathogen is likely MDR (especially carbapenem‑resistant Enterobacteriaceae or Acinetobacter).
  3. Combination therapy improves success for MDR Gram‑negative infections; common partners are colistin, polymyxin B, or a high‑dose β‑lactam.
  4. Monitor MICs – a tigecycline MIC of 1 mg/L is a good target; ≥ 2 mg/L predicts a higher failure risk.
  5. Adjust dosing – for ICU patients, consider the 100 mg q12 h regimen and longer duration if source control is delayed.

Quick reference table (overall success rates)

Infection Typical success rate (monotherapy) Typical success rate (combination)
cIAI 65–75 % 70–80 %
cSSSI 60–70 % 70–80 %
CAP 65–75 % 70–80 %
MDR Acinetobacter 40–55 % 65–75 %
MDR Enterobacteriaceae 45–60 % 70–85 %

These ranges come from pooled analyses of RCTs, large‑cohort studies, and real‑world surveillance reports up to 2023. Individual patient factors (age, comorbidities, organ dysfunction) can shift the actual numbers.

Bottom line: Tigecycline works well enough as monotherapy in many common infections, but its success rates dip notably in severe or MDR settings—where a combination approach is usually preferred.



Other Questions About Tigecycline :

Is tigecycline a common cure for certain diseases? Which bacteria exhibit tigecycline resistance? Does increasing tigecycline dose alter bacterial sensitivity? What were the outcomes of tigecycline combined trials? How can these drug interactions affect tigecycline's efficacy? Are there any promotions currently running for tigecycline? How does tigecycline resistance emerge with overuse?